# IMpower 133 (NCT02763579)

> A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02763579
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Small Cell Lung Carcinoma
- Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody; Carboplatin; Etoposide; Placebo
- Enrollment: 503
- Primary outcome: Duration of Progression-Free Survival (PFS) as Assessed by the Investigator Using RECIST v1.1 in the Global Population
- Primary outcome: Duration of Overall Survival (OS) in the Global Population

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 62
- YouTube: 56
- X threads: 46
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=impower-133-nct02763579

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02763579", "email": "<work email>"}; the inbox owner confirms by the emailed link.